circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Barclays Global Healthcare Conference
    Mar 11, 2021 9:45 AM EST

    Barclays Global Healthcare Conference
    Mar 11, 2021 9:45 AM EST
  • Webcast
    X H.C. Wainwright Global Life Sciences Conference
    Mar 9, 2021 7:00 AM EST

    H.C. Wainwright Global Life Sciences Conference
    Mar 9, 2021 7:00 AM EST
  • Webcast
    X Q4 2020 Cytokinetics, Inc. Earnings Conference Call
    Feb 25, 2021 4:00 PM EST

    Q4 2020 Cytokinetics, Inc. Earnings Conference Call
    Feb 25, 2021 4:00 PM EST

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10,
Toggle Summary Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 26, 2021 it granted stock options to purchase an aggregate of 9,000 shares of common stock to Wing Keung Chiu , a new employee whose employment commenced in
Toggle Summary Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that on February 28 it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®,
Toggle Summary Cytokinetics Reports Fourth Quarter 2020 Financial Results
Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF Enrollment Completed in Cohort 2 of REDWOOD-HCM; Results Expected Mid-Year Company Provides 2021 Financial Guidance; More Than Two Years of Cash Runway SOUTH SAN FRANCISCO, Calif. , Feb.